Press Release Details
Exagen to Announce Second Quarter Financial Results on July 28, 2020
Interested parties may access the conference call by dialing (877) 407-3982 (
A replay of the conference call will be available until
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.
CONTACTS:
Investors
Mike.Cavanaugh@westwicke.com
646.677.1838
Company Contact
KAdawi@exagen.com
760.477.5514
Source: Exagen Inc.